The IPCGOR combined with IL-2 treatment delivers chemotherapeutic drugs directly to the patient's thoracic cavity through a catheter, directly killing NSCLC cells through toxic reactions and activating immunity through IL-2. The gene discussed is IL2; the disease is non-small cell lung carcinoma.